Sonnet BioTherapeutics (SONN)

• Market cap: $28.4M
• 1 day: 0%
• 5 days: -9.57%
• 1 month: -28.89%
• 3 months: 15.24%
• 6 months: 249.58%
• Year to date: 160%
• 1 year: 50.18%
• 5 years: -99.93%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Employees: 13